fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Diabetes advocacy group discourages use

Some people naturally have more responsive GLP-1 receptors in their hypothalamus, leading to earlier and more pronounced appetite suppression

Supplementary data The following is the Supplementary data to this article: References 1.Nouwen A., Winkley K., Twisk J., Lloyd C.E., Peyrot M., Ismail K., et al

For approved drugs in the same class (semaglutide, tirzepatide), the general guidance is to take the missed dose as soon as possible if within a few days, then resume the regular weekly schedule

While we expect this pivot to continue to be disruptive in the short-term, we believe it will lead to long-term growth and refinement of a strategy that we could utilise out of the gate in the US market. With the new strategic direction and near-term disruption, management expects preliminary, unaudited revenue for the second quarter of 2025 to be approximately $3 million and an operating loss of approximately $7 million as compared to an operating loss of $9.3 million in the second quarter of 2024